Investigating the impact of programmed cell death logand-1 (PD-L1) expression in lung cancer on long-term outcome and therapeutic effect of anti-programmed cell death-1 antibody agents.
Not Applicable
- Conditions
- lung cancer
- Registration Number
- JPRN-UMIN000025395
- Lead Sponsor
- Kansai Medical University
- Brief Summary
General agreement in tumoral PD-L1 detection between 22C3 and 28-8 was satisfactory. Dako 22C3 revealed a significantly higher tumoral PD-L1 expression compared to 28-8. Positive results of 22C3 (reference) and those of 28-8 (comparator) showed discordance. The results of 28-8 could be translated to those of 22C3 but not vice versa.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 420
Inclusion Criteria
Not provided
Exclusion Criteria
#1 Patients with inadequate amount of their pathological sample for this study #2 Patients refusing to be enrolled in this study #3 Patients who is judged as not suitable by the administrator of this study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Protein expression of PD-L1 in lung cancer tissue
- Secondary Outcome Measures
Name Time Method #1 Overall survival according to PD-L1 expression #2 Recurrence-free survival according to PD-L1 expression in patients undergoing complete resection for their lung cancer #3 Progression-free survival according to PD-L1 expression in patients receiving anti-PD-1 antibody agents